CRSP · CRISPR Therapeutics AG — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on CRSP. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About CRSP · CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Live Quote
HOLD (score +1) · 12-1 mom 6.7% · RSI 54.4 · above_50_only · -29.7% from high
Targets blend Wall Street consensus (21 analysts: low $44.00 / mean $83.52 / high $291.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
CRSP is a pre-revenue gene editing biotech with one approved therapy (CASGEVY, partnered to Vertex) and multiple pipeline programs in various stages of development. The company burns ~$130M/quarter in cash while generating minimal collaboration revenue ($1-4M/quarter). CASGEVY uptake has been slower than expected per Vertex's guidance, limiting near-term royalty upside for CRSP. The stock trades 27% off its 52-week high and is approaching that range ceiling after a +9% single-day surge on June 5 (likely triggered by Eli Lilly competitive data news re-framing the sector narrative). No open-market insider purchases were detected in the trailing period — all recent Form 4s reflect RSU grants to executives, not buys. There are upcoming binary catalysts including zugo-cel autoimmune Phase 1/2 data and CTX310 Phase 1b readout expected H2 2026, but these are speculative outcomes with no confirmed timing. The balance sheet shows $2.44B in cash against ~$585M in long-term debt; runway extends to approximately mid-2027 at current burn rates without additional partnership payments. No clear mispricing relative to biotech peers given the pre-profitability status and negative FCF.
CRISPR Therapeutics is a pre-commercial gene-editing biotech whose sole approved product CASGEVY (co-commercialized with Vertex) showed weak Q1 2026 results — EPS missed by -12.4%, revenue by -82.6%. A $700M convertible notes offering in March 2026 further diluted shareholders without resolving the fundamental burn problem (~-$260M FCF annually). No open-market insider purchases from CEO/CFO exist in recent filings; Form 4 activity reflects RSU vesting and option exercises only, not directional conviction buys. Options flow is put-heavy (PC ratio 1.31) with no whale blocks, technicals show the stock below its 200DMA after falling ~30% from October 2025 highs near $77 to current ~$55. No named catalyst in the 3-12 month window that would force a re-rating — pipeline programs are 2-4 years from approval and market already appears to be discounting significant CASGEVY commercial uptake that has not materialized.